EOLS
NASDAQ HealthcareEvolus, Inc. - Common Stock
Drug Manufacturers - Specialty & Generic
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
๐ Market Data
| Price | $7.52 |
|---|---|
| Volume | 789,229 |
| Market Cap | 496.70M |
| Beta | 1.340 |
| RSI (14-Day) | 46.3 |
| 200-Day MA | $6.25 |
| 50-Day MA | $8.00 |
| 52-Week High | $9.31 |
| 52-Week Low | $3.86 |
| Forward P/E | 25.71 |
| Price / Book | -16.07 |
๐ฏ Investment Strategy Scores
EOLS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (79/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Institutional Whale (12/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find EOLS in your text
Paste any article, transcript, or post โ the tool will extract EOLS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-10-29.